- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Contact us
- Thank you
PERFADEX® and STEEN Solution™ approved in Russia
Russia’s Federal Service for Supervision on Health Care has approved PERFADEX® and STEEN Solution™ for lung transplantation. This means that PERFADEX® and STEEN Solution™ may be sold for clinical use in Russia.
Russia is not a large market today, but there is a great need for more lung transplants to be performed in the region. This registration allows clinics in Russia to gain access to PERFADEX®, which is adapted to lung preservation, and to be able to evaluate the quality of lungs using STEEN Solution™ and Ex Vivo Lung Perfusion (EVLP).
“The registration of PERFADEX® and STEEN Solution™ in Russia increases the accessibility of lung transplant products in this region and is a step in the right direction towards our vision that “No-one should need to die waiting for a new organ”. It is also in line with our long-term focus on future growth markets,” says Magnus Nilsson, CEO of XVIVO Perfusion.
February 16, 2016
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, firstname.lastname@example.org
Magnus Nilsson, CEO, +46 31 788 2150, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on February 16, 2016 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.